Variations in parthenolide content and daily dose of feverfew products

被引:25
作者
Nelson, MH [1 ]
Cobb, SE [1 ]
Shelton, J [1 ]
机构
[1] SW Oklahoma State Univ, Sch Pharm, Weatherford, OK 73096 USA
关键词
alternative medicine; analysis; chromatography; liquid; concentration; content uniformity; control; quality; dietary supplements; dosage; labeling; parthenolide; plants; Tanacetum parthenium;
D O I
10.1093/ajhp/59.16.1527
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Variations in the parthenolide content of feverfew products available to consumers were studied. Feverfew products were analyzed for the content of parthenolide, the purported active component. The actual weight of feverfew was determined only in those products containing dried feverfew leaf. The total daily doses of feverfew leaf and parthenolide content were calculated by using the instructions on each product label. Parthenolide content was determined by high performance liquid chromatography. The quantity of feverfew leaf in each capsule was similar to that stated on the label and ranged from 25 to 500 mg. Parthenolide content per dosage form varied 150-fold (from 0.02 to 3.0 mg), while percent parthenolide varied 5.3-fold (from0.14% to 0.74%). If a person consumed the daily dose recommended on the label, intake of dried feverfew leaf would range from 225 to 2246 mg/day, a 10-fold variation, while intake of parthenolide would range from 0.06 to 9.7 mg/day, a 160-fold variation. Large variations were observed in the parthenolide contents and daily intake as, recommended by the labeling in commercial feverfew products.
引用
收藏
页码:1527 / 1531
页数:5
相关论文
共 16 条
[1]   PARTHENOLIDE CONTENT OF FEVERFEW (TANACETUM-PARTHENIUM)ASSESSED BY HPLC AND H-1-NMR SPECTROSCOPY [J].
AWANG, DVC ;
DAWSON, BA ;
KINDACK, DG ;
CROMPTON, CW ;
HEPTINSTALL, S .
JOURNAL OF NATURAL PRODUCTS, 1991, 54 (06) :1516-1521
[2]  
BARSBY RWJ, 1991, J PHARM PHARMACOL, V44, P737
[3]   Pharmacological activity of feverfew (Tanacetum parthenium (L) Schultz-Bip): Assessment by inhibition of human polymorphonuclear leukocyte chemiluminescence in-vitro [J].
Brown, AMG ;
Edwards, CM ;
Davey, MR ;
Power, JB ;
Lowe, KC .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (05) :558-561
[5]  
DERMARDEROSIAN A, 1999, GUIDE POPULAR NATURL
[6]  
Fetrow C, 1999, PROFESSIONALS HDB CO
[7]   COMPOUNDS EXTRACTED FROM FEVERFEW THAT HAVE ANTI-SECRETORY ACTIVITY CONTAIN AN ALPHA-METHYLENE BUTYROLACTONE UNIT [J].
GROENEWEGEN, WA ;
KNIGHT, DW ;
HEPTINSTALL, S .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1986, 38 (09) :709-712
[8]   A COMPARISON OF THE EFFECTS OF AN EXTRACT OF FEVERFEW AND PARTHENOLIDE, A COMPONENT OF FEVERFEW, ON HUMAN PLATELET ACTIVITY INVITRO [J].
GROENEWEGEN, WA ;
HEPTINSTALL, S .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1990, 42 (08) :553-557
[9]  
GROENEWEGEN WA, 1986, LANCET, V1, P44
[10]   Content versus label claims in ephedra-containing dietary supplements [J].
Gurley, BJ ;
Gardner, SF ;
Hubbard, MA .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (10) :963-969